2.75 x 12.5 Inner 2.50 1/2 12 Rocket Bike Dirt MX400 / MX350 Razor for Tube Parts & Accessories


  1. Home
  2. 2.75 x 12.5 Inner 2.50 1/2 12 Rocket Bike Dirt MX400 / MX350 Razor for Tube
  1. facebook
  2. twitter
  3. linkedin
  4. pinterest
12.5 x 2.75 Inner Tube for Razor MX350 / MX400 Dirt Bike Rocket 12 1/2 2.50
Condition: New: A brand-new, unused, unopened, undamaged item in its original packaging (where packaging is Brand:

Qind

MPN:

48-0250

UPC:

722460303711

published on tue nov 09 2021

2.75 x 12.5 Inner 2.50 1/2 12 Rocket Bike Dirt MX400 / MX350 Razor for Tube Parts & Accessories

gandhi, s., klein, j., robertson, a., pena-hernandez, m. a.,

2.75 x 12.5 Inner 2.50 1/2 12 Rocket Bike Dirt MX400 / MX350 Razor for Tube Parts & Accessories

lin, m. j., roychoudhury, p., lu, p., fournier, j., ferguson, d., mohamed bakhash, s. a., muenker, m. c., srivathsan, a., wunder, e. a., kerantzas, n., wang, w., pyle, a., wilen, c. b., ogbuagu, o., greninger ,, a. l., iwasaki, a., schulz, w. l., ko, a. i.

sars-cov-2 remdesivir resistance mutations have been generated in vitro but have not been reported in patients receiving treatment with the antiviral agent. we present a case of an immunocompromised patient with acquired b-cell deficiency who developed an indolent, protracted course of sars-cov-2 infection. remdesivir therapy alleviated symptoms and produced a transient virologic response, but her course was complicated by recrudescence of high-grade viral shedding. whole genome sequencing identified a mutation, e802d, in the nsp12 rna-dependent rna polymerase which was not present in pre-treatment specimens. in vitro experiments demonstrated that the mutation conferred a ~6-fold increase in remdesivir ic50 but resulted in a fitness cost in the absence of remdesivir. sustained clinical and virologic response was achieved after treatment with casirivimab-imdevimab. although the fitness cost observed in vitro may limit the risk posed by e802d,

, this case illustrates the importance of monitoring for remdesivir resistance and the potential benefit of combinatorial therapies in immunocompromised patients with sars-cov-2 infection.

509
1.2k
EVGENIA.RU RSS